Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Conatus Pharmaceuticals CNAT

Healthcare Biotechnology
Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes... see more

Recent & Breaking News (NDAQ:CNAT)

Conatus Pharmaceuticals Inc. (NASDAQ: CNAT) FDA has Granted Fast Track Designation for Emricasan Analyst Comments

Accesswire February 9, 2016

FDA Grants Conatus Fast Track Designation for Development of Emricasan in NASH Cirrhosis

GlobeNewswire February 3, 2016

Conatus to Present at BIO CEO & Investor Conference

GlobeNewswire February 2, 2016

Conatus Initiates Phase 2b ENCORE-NF Clinical Trial of Emricasan in Patients With NASH Fibrosis

GlobeNewswire January 11, 2016

Conatus Achieves Positive Results with Emricasan in Initial Stage of Phase 2 Liver Cirrhosis Clinical Trial

GlobeNewswire January 5, 2016

Conatus Pharmaceuticals Announces Late-Breaking Oral Presentation at AASLD Annual Meeting

GlobeNewswire November 16, 2015

Conatus Pharmaceuticals Announces Poster Presentations at AASLD Annual Meeting

GlobeNewswire November 16, 2015

Conatus Pharmaceuticals Announces Selection of Late-Breaking Oral Presentation as Noteworthy Abstract to be Highlighted in AASLD President's Press Conference at AASLD Annual Meeting

GlobeNewswire November 14, 2015

Conatus Pharmaceuticals to Present at Stifel 2015 Healthcare Conference

GlobeNewswire November 11, 2015

Conatus Pharmaceuticals Reports Third Quarter 2015 Financial Results and Program Updates

GlobeNewswire November 4, 2015

Biotech Bonanza: 4 Stocks With Pending Clinical or Preclinical News (And Why the Results Will Move the Stocks)

Accesswire November 2, 2015

Conatus Pharmaceuticals to Report Third Quarter 2015 Financial Results

GlobeNewswire October 28, 2015

Conatus Pharmaceuticals Announces Acceptance of Late-Breaking Abstract for AASLD Annual Meeting

GlobeNewswire October 20, 2015

Conatus Pharmaceuticals Announces Acceptance of Abstracts for AASLD Annual Meeting

GlobeNewswire October 1, 2015

Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis

GlobeNewswire September 23, 2015

Conatus Pharmaceuticals Reports Second Quarter 2015 Financial Results and Program Updates

GlobeNewswire August 5, 2015

Conatus Pharmaceuticals to Report Second Quarter 2015 Financial Results

GlobeNewswire July 29, 2015

Conatus Announces Initial Baseline Data From Phase 2b POLT-HCV-SVR Clinical Trial of Emricasan Confirming Activity of Relevant Mechanisms and Opportunity for Histological Improvement

GlobeNewswire June 25, 2015

Conatus Pharmaceuticals Appoints Mason M. Yamashita as Vice President, Pharmacovigilance

GlobeNewswire June 22, 2015

Conatus Pharmaceuticals Appoints Jean L. Chan as Vice President, Clinical Development

GlobeNewswire June 8, 2015